Research and Development Department, Multi-Chemical Industry, Lot 157, Z I, Sud-Ouest (ERAC) B.P.: 278, Mohammedia 28810, Morocco
Original Research Article
Duration of Immunogenicity of the Recombinant Rift Valley Fever Vaccine MP-12 del-NSm21/384 in Sheep
Author(s): Zahra Bamouh, Zineb Boumart, Meryem Alhyane, Khalid Omari Tadlaoui, George E Bettinger, Douglas M Watts*, Ouafaa Fassi Fihri and Mehdi EL Harrak
Rift Valley Fever Virus (RVFV) is a mosquito-transmitted Bunyavirus capable of causing high morbidity and mortality
among humans and domestic ruminants. Vaccination of domestic ruminants with vaccines that provide safe, rapid
and long-term protection after a single vaccination is an effective strategy for protecting animals against Rift Valley
Fever (RVF) disease. The aim of this study was to determine the duration and titer of antibody elicited by the
RVF MP-12 del-NSm21/384 vaccine in sheep. Serum samples were collected from the animals before and after
vaccination at various intervals up to one-year post vaccination to determine the duration of the antibody response
using a virus-neutralizing test. All vaccinated sheep remained healthy, and RVFV antibody was first detected at two
weeks post-vaccination in 37.5% of vaccinated sheep and 100% at three wee.. View more»